Find the latest oncology news for your sub-specialty area
EHA: Cerdulatinib demonstrates rapid tumour responses in a phase 2 study for relapsed/refractory NHL
Cerdulatinib is an oral, dual Syk-JAK inhibitor with a unique mechanism of action. It inhibits…